Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RepliCel Poised To Partner Up For Precision-Control Dermal Injector

Executive Summary

RepliCel Life Sciences is set to unveil in July the first functioning prototype of its next-generation dermal injector, which the company said has already sparked the interest of big dermal filler manufacturers. While the technology had been developed originally to deliver RepliCel's cell therapies for pattern baldness and aging or sun-damaged skin, the company believes the injector's unique features – including electronically-controlled dosing and delivery – allow it to be used in myriad applications.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT105048

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel